Project Grant F30CA287907
Award Date
9/27/24
Completion Date
3/31/28
Dollars Obligated
$233K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
Maywood, IL 60153, USA
Similar Awards
The National Cancer Institute (CFDA 93.396 - Cancer Biology Research) awarded Loyola University of Chicago a $461,844 project grant titled "Hyperpolarized 13C Metabolic Imaging of Tumorigenesis in the Liver". The objective is to use novel hyperpolarized 13C probes to image glycolysis, a critical pathway in hepatocellular carcinoma (HCC) development, and establish in vivo imaging biomarkers to assess altered liver metabolism during HCC progression. The project aims to synthesize a...
This $127,952 Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) will support research at George Washington University to study the role of the enzyme HDAC11 in liver cancer progression. The research has two main aims: 1) to determine if HDAC11-mediated modifications to the splicing factor SF3B2 impact alternative mRNA splicing in liver cancer cells, and 2) to evaluate the potential of HDAC11-specific inhibitors as a new liver cancer treatment...
This federal Project Grant award of $599,299 from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research at the University of Illinois to investigate the role of the enzyme hexokinase 2 (HK2) in liver fibrosis and its connection to non-alcoholic steatohepatitis (NASH)-induced hepatocellular carcinoma (HCC). The research aims to further validate the importance of HK2 in liver fibrosis development and its impact on NASH-induced HCC, a leading cause of...
This Project Grant award, titled "EXPLOITING THERAPEUTIC VULNERABILITIES IN HEPATOCELLULAR CARCINOMA (ELEVATE)", is funded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research). The $2,678,459 award aims to advance the understanding of molecular mechanisms regulating non-alcoholic steatohepatitis (NASH)-associated hepatocellular carcinoma (HCC) and develop novel combinatorial treatment approaches. The award supports four research projects, an administrative core, a...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $518,219 in funding to the University of Pittsburgh to conduct research aimed at deciphering the molecular mechanisms underlying the development of cholangiocarcinoma (CCA), a deadly form of liver cancer. The key objectives of this 5-year research project are to: Investigate the intertwined roles of the nuclear receptors FXR and CAR in promoting the malignant transformation of hepatocytes...
The National Cancer Institute (NCI) awarded a Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, Massachusetts. The $172,193 grant, awarded on May 7, 2025, supports a 5-year research project to characterize gene regulatory elements and metabolic functions in a rare and aggressive form of renal cell carcinoma known as translocation renal cell carcinoma (TRCC). The research aims to develop optimization methods to...
The National Cancer Institute (NCI), under the Federal Grant Program "Cancer Research Manpower" (CFDA 93.398), awarded a Project Grant in the amount of $145,336 to the Sloan-Kettering Institute for Cancer Research located in New York. The grant, titled "Metabolically Reprogramming Hepatic Macrophages to Conquer Immune Desert Tumors," will fund research focused on reprogramming hepatic macrophages to overcome the "immune-desert" phenotype of B-catenin-driven...
The National Cancer Institute (NCI) awarded a $177,000 Project Grant under the Cancer Biology Research program (CFDA 93.396) to The Children's Hospital Corporation, doing business as Boston Children's Hospital. The funding supports research to investigate the role of the NLRC4 inflammasome and caspase-8 activation in the pathogenesis of fibrolamellar carcinoma (FLC), a rare and aggressive form of liver cancer. The researchers will use mouse liver organoids engineered with the DNAJB1-PRKACA...
The National Cancer Institute (NCI) awarded a 5-year, $646,739 Project Grant (CFDA 93.396 - Cancer Biology Research) to Cedars-Sinai Medical Center to investigate the role of hepatic stellate cells (HSCs) in promoting liver metastasis in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). The research aims to elucidate the regulatory mechanisms and functional roles of extra-tumoral and intra-tumoral HSCs, as well as the impact of extracellular matrix (ECM)...
This $521,579 Project Grant award, provided by the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), supports research to identify critical regulators controlling clear cell renal cell carcinoma (CCRCC) lung metastasis. The University of Texas Southwestern Medical Center, the awardee, will conduct a genome-wide CRISPR screen to characterize the role of the hepatic leukemia factor (HLF) in CCRCC lung metastasis and examine the underlying molecular...